UNSPSC 51332501: Haloperidol

This classification denotes a butyrophenone with the molecular formula C21H23ClFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J6292F8L3D, chemically known as 1-butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as haloperidol, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules Haloperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08005MIG. The term HALOPERIDOL is an International Non-Proprietary Name.

UNSPSC 51332501 Haloperidol, a Commodity code, names a specific pharmaceutical product, but recent state and local procurement activity tagged to this code does not align with haloperidol procurement itself. The solicitations instead reflect broader pharmaceutical supply, opioid-reversal medication, and drug-handling systems relevant to public health and human services agencies. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances acting on behalf of state and local government facilities. The work under this code involves sourcing pharmaceuticals and related medical products through competitive bidding, RFP, and cooperative purchasing vehicles—contracts typically structured with unit pricing, delivery schedules, volume commitments, and compliance requirements including cGMP certification, DSCSA compliance, E-Verify verification, and federal insurance standards.

Recent activity spans Florida, Texas, and Minnesota-led multistate procurement. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, response due March 26, 2026, requiring NDC-specific pricing and supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson). Cooperative purchasing vehicles dominate the code's recent activity, indicating that state and local buyers increasingly pool demand through multistate alliances rather than issuing individual procurements. Set-asides and disadvantaged-enterprise designations do not appear in the recent opportunities cited.